Research ExplorerPublicationsEULAR study group on 'MHC-I-opathy'

EULAR study group on 'MHC-I-opathy'

Standard

EULAR study group on 'MHC-I-opathy' : identifying disease-overarching mechanisms across disciplines and borders. / Kuiper, Jonas Jw; Prinz, Jörg C; Stratikos, Efstratios; Kuśnierczyk, Piotr; Arakawa, Akiko; Springer, Sebastian; Mintoff, Dillon; Padjen, Ivan; Shumnalieva, Russka; Vural, Seçil; Kötter, Ina; van de Sande, Marleen G; Boyvat, Ayşe; de Boer, Joke H; Bertsias, George; de Vries, Niek; Krieckaert, Charlotte Lm; Leal, Inês; Vidovič Valentinčič, Nataša; Tugal-Tutkun, Ilknur; El Khaldi Ahanach, Hanane; Costantino, Félicie; Glatigny, Simon; Mrazovac Zimak, Danijela; Lötscher, Fabian; Kerstens, Floor G; Bakula, Marija; Viera Sousa, Elsa; Böhm, Peter; Bosman, Kees; Kenna, Tony J; Powis, Simon J; Breban, Maxime; Gul, Ahmet; Bowes, John; Lories, Rik Ju; Nowatzky, Johannes; Wolbink, Gerrit Jan; McGonagle, Dennis G; Turkstra, Franktien; EULAR studygroup MHC-I-opathies.

In: ANN RHEUM DIS, Vol. 82, No. 7, 07.2023, p. 887-896.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Kuiper, JJ, Prinz, JC, Stratikos, E, Kuśnierczyk, P, Arakawa, A, Springer, S, Mintoff, D, Padjen, I, Shumnalieva, R, Vural, S, Kötter, I, van de Sande, MG, Boyvat, A, de Boer, JH, Bertsias, G, de Vries, N, Krieckaert, CL, Leal, I, Vidovič Valentinčič, N, Tugal-Tutkun, I, El Khaldi Ahanach, H, Costantino, F, Glatigny, S, Mrazovac Zimak, D, Lötscher, F, Kerstens, FG, Bakula, M, Viera Sousa, E, Böhm, P, Bosman, K, Kenna, TJ, Powis, SJ, Breban, M, Gul, A, Bowes, J, Lories, RJ, Nowatzky, J, Wolbink, GJ, McGonagle, DG, Turkstra, F & EULAR studygroup MHC-I-opathies 2023, 'EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders', ANN RHEUM DIS, vol. 82, no. 7, pp. 887-896. https://doi.org/10.1136/ard-2022-222852

APA

Kuiper, J. J., Prinz, J. C., Stratikos, E., Kuśnierczyk, P., Arakawa, A., Springer, S., Mintoff, D., Padjen, I., Shumnalieva, R., Vural, S., Kötter, I., van de Sande, M. G., Boyvat, A., de Boer, J. H., Bertsias, G., de Vries, N., Krieckaert, C. L., Leal, I., Vidovič Valentinčič, N., ... EULAR studygroup MHC-I-opathies (2023). EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders. ANN RHEUM DIS, 82(7), 887-896. https://doi.org/10.1136/ard-2022-222852

Vancouver

Kuiper JJ, Prinz JC, Stratikos E, Kuśnierczyk P, Arakawa A, Springer S et al. EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders. ANN RHEUM DIS. 2023 Jul;82(7):887-896. https://doi.org/10.1136/ard-2022-222852

Bibtex

@article{1e8b53fd212f4aeba630dbc62e1b84d2,
title = "EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders",
abstract = "The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Beh{\c c}et's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.",
keywords = "Humans, Genetic Predisposition to Disease, Uveitis, Behcet Syndrome/genetics, Histocompatibility Antigens Class I/genetics, Spondylarthritis, Aminopeptidases/genetics, Minor Histocompatibility Antigens/genetics",
author = "Kuiper, {Jonas Jw} and Prinz, {J{\"o}rg C} and Efstratios Stratikos and Piotr Ku{\'s}nierczyk and Akiko Arakawa and Sebastian Springer and Dillon Mintoff and Ivan Padjen and Russka Shumnalieva and Se{\c c}il Vural and Ina K{\"o}tter and {van de Sande}, {Marleen G} and Ay{\c s}e Boyvat and {de Boer}, {Joke H} and George Bertsias and {de Vries}, Niek and Krieckaert, {Charlotte Lm} and In{\^e}s Leal and {Vidovi{\v c} Valentin{\v c}i{\v c}}, Nata{\v s}a and Ilknur Tugal-Tutkun and {El Khaldi Ahanach}, Hanane and F{\'e}licie Costantino and Simon Glatigny and {Mrazovac Zimak}, Danijela and Fabian L{\"o}tscher and Kerstens, {Floor G} and Marija Bakula and {Viera Sousa}, Elsa and Peter B{\"o}hm and Kees Bosman and Kenna, {Tony J} and Powis, {Simon J} and Maxime Breban and Ahmet Gul and John Bowes and Lories, {Rik Ju} and Johannes Nowatzky and Wolbink, {Gerrit Jan} and McGonagle, {Dennis G} and Franktien Turkstra and {EULAR studygroup MHC-I-opathies}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2023",
month = jul,
doi = "10.1136/ard-2022-222852",
language = "English",
volume = "82",
pages = "887--896",
journal = "ANN RHEUM DIS",
issn = "0003-4967",
publisher = "BMJ PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - EULAR study group on 'MHC-I-opathy'

T2 - identifying disease-overarching mechanisms across disciplines and borders

AU - Kuiper, Jonas Jw

AU - Prinz, Jörg C

AU - Stratikos, Efstratios

AU - Kuśnierczyk, Piotr

AU - Arakawa, Akiko

AU - Springer, Sebastian

AU - Mintoff, Dillon

AU - Padjen, Ivan

AU - Shumnalieva, Russka

AU - Vural, Seçil

AU - Kötter, Ina

AU - van de Sande, Marleen G

AU - Boyvat, Ayşe

AU - de Boer, Joke H

AU - Bertsias, George

AU - de Vries, Niek

AU - Krieckaert, Charlotte Lm

AU - Leal, Inês

AU - Vidovič Valentinčič, Nataša

AU - Tugal-Tutkun, Ilknur

AU - El Khaldi Ahanach, Hanane

AU - Costantino, Félicie

AU - Glatigny, Simon

AU - Mrazovac Zimak, Danijela

AU - Lötscher, Fabian

AU - Kerstens, Floor G

AU - Bakula, Marija

AU - Viera Sousa, Elsa

AU - Böhm, Peter

AU - Bosman, Kees

AU - Kenna, Tony J

AU - Powis, Simon J

AU - Breban, Maxime

AU - Gul, Ahmet

AU - Bowes, John

AU - Lories, Rik Ju

AU - Nowatzky, Johannes

AU - Wolbink, Gerrit Jan

AU - McGonagle, Dennis G

AU - Turkstra, Franktien

AU - EULAR studygroup MHC-I-opathies

N1 - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2023/7

Y1 - 2023/7

N2 - The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.

AB - The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.

KW - Humans

KW - Genetic Predisposition to Disease

KW - Uveitis

KW - Behcet Syndrome/genetics

KW - Histocompatibility Antigens Class I/genetics

KW - Spondylarthritis

KW - Aminopeptidases/genetics

KW - Minor Histocompatibility Antigens/genetics

U2 - 10.1136/ard-2022-222852

DO - 10.1136/ard-2022-222852

M3 - SCORING: Review article

C2 - 36987655

VL - 82

SP - 887

EP - 896

JO - ANN RHEUM DIS

JF - ANN RHEUM DIS

SN - 0003-4967

IS - 7

ER -